As of December 31, 2023, VYNE had cash, cash equivalents, restricted cash and marketable securities of $93.3 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of December 31, 2023 will be sufficient to fund its operations through the end of 2025
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYNE:
- VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update
- VYNE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- VYNE Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference
- VYNE Therapeutics Announces Positive Biomarker Data from Successful Phase 1b Trial of VYN201 for the Treatment of Vitiligo
- VYNE Therapeutics announces biomarker data from Phase 1b trial of VYN201
